On March 27, 2014, Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) issued a press release announcing its financial results for the quarter and year ended December 31, 2013. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) stock performance was -15.63% in last session and finished the day at $8.42. Traded volume was 1.28 million shares in the last session and the average volume of the stock remained 473,716.00 shares. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) insider ownership is 0.30%.

On March 27, 2014, Metabolix, Inc. (NASDAQ:MBLX) issued a press release announcing the financial results for its year ended December 31, 2013. Metabolix, Inc. (NASDAQ:MBLX) dropped -14.29% to $1.20 Friday on volume of 405,500.00 shares. The intra-day range of the stock was $1.10 – $1.28. Metabolix, Inc. (NASDAQ:MBLX) has a market capitalization of 41.50 million.

Boulder-based Clovis Oncology Inc. (NASDAQ:CLVS) (NASDAQ:CLVS) reported Thursday from a conference in Geneva, Switzerland, that it’s orally delivered drug, CO-1686, is providing benefits to patients suffering from lung cancer and is being well-tolerated as doses are increased. Clovis Oncology Inc. (NASDAQ:CLVS)’s stock on March 28, 2014 reported a lower of -12.44% to the closing price of $70.33. Its fifty two weeks range is $27.17 – $93.33. The total market capitalization recorded 2.38 billion. The overall volume in the last trading session was 1.89 million shares. In its share capital, Clovis Oncology Inc. (NASDAQ:CLVS) has 33.90 million outstanding shares.

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), on March 27 announced the appointment of Sharon Barbari to its board of directors, effective March 26, 2014. On Friday, shares of Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) dropped -11.49% to close the day at $3.85. Company return on investment (ROI) is -54.10% and its monthly performance is recorded as -1.03%. Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) quarterly revenue growth is 6.06%.